SPIE.WEST presentation on light delivery technology for PDTTowards high-throughput light-activated drug discovery with automated plate illuminator 6 - 11 March 2021 This
SPIE.PHOTONICS.WEST presentation will demonstrate how the
ML8500 automatic biomedical illumination system would work with
Dr. McFarland's new ruthenium and osmium compounds in targeting various forms of cancer in normoxic and hypoxic conditions using different wavelengths, doses and intensities of light.
Dr. McFarland has used a
Modulight laser system for years in her experiments wirh PDCs and even did a promo for the Finnish based company when she was at
UNCG. A video of the promo can be seen here:
https://www.modulight.com/company/ The
ML8500 automatic biomedical illumination system can be used in conjunction with a 96-well plate, each well of which can be illuminated separately with a specific duration, and intensity by an 8 channel laser. Each of these parameters can be pre-programmed for each well with an easy to use program. There is a very interesting video about how it works on youtube:
ML8500 Biomedical illumination system Spie Presentation Authors: Presenter/Author Robert Perttil
Modulight, Inc. (Finland)
Author John Roque III
The Univ. of Texas at Arlington (United States)
Author Lasse Orsila
Modulight, Inc. (Finland), Tampere Univ. Hospital (Finland)
Author Zoe Ylniemi
Modulight, Inc. (Finland)
Author Elias Kokko
Modulight, Inc. (Finland)
Author Colin G. Cameron
The Univ. of Texas at Arlington (United States)
Author Sherri A. McFarland
The Univ. of Texas at Arlington (United States)
Author Petteri Uusimaa
Modulight, Inc. (Finland)
Abstract
There is an ongoing need in photodynamic therapy (PDT) research to develop highly active photosensitizers (PSs) with improved characteristics combined with optimized treatment protocols to produce effective treatment with minimal side effects. While several novel PSs have undergone clinical trials or been approved in recent years, there remain few available instrumentation options for high-throughput screens (HTS) with in vitro PDT. The Modulight ML8500 was developed to address this need, facilitating HTS of potential PSs with its precisely specific control over the light component. The instrument can select from a variety of high-power, monochromatic wavelengths for screening in the context of a tumor-centered approach, whereby the light dose can be tailored to optimize for physiological conditions or limitations specific to the type of cancer. In the present case, the ML8500 was used here to characterize a series of promising ruthenium-based complexes specifically designed to target melanoma. These PSs could be activated over a broad range of wavelengths, and most importantly including in the near-infrared range, where light penetrates tissue more effectively. In a second study, osmium-based PSs were characterized with the ML8500 in normoxic and hypoxic conditions with variable light parameters (wavelength, light dose, light fluence), showing high activity even in hypoxic conditions. These are specific examples where the ML8500 successfully increased experimental flexibility, reproducibility, and throughput.